BETA
Your AI-Trained Oncology Knowledge Connection!
Managing Colorectal Cancer Requires Using All Available Options
In an interview with Peers & Perspectives in Oncology, John L. Marshall, MD, discussed treatment approaches and sequencing for refractory colorectal cancer.
Westin Discusses Logistical and Tolerability Challenges in Metastatic Cervical Cancer
During a live event, Shannon N. Westin, MD, MPH, and participants discussed their experience treating patients with progressive cervical cancer and the toxicity profile of tisotumab vedotin.
Jacobson Discusses Second and Third-Line Options for DLBCL
During a live event, Caron A. Jacobson, MD, MMSc, and participants discussed how they decide on therapy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Voss Examines TKI/IO and IO/IO Regimens in Non–Clear Cell RCC
During a live event, Martin Voss, MD, reviewed the trials of lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and ipilimumab plus nivolumab in non–clear cell renal cell carcinoma.
Hoffmann Examines Data for 17p Deletion in Treatment-Naive CLL
During a live event, Marc S. Hoffmann, MD, discussed outcomes from the SEQUOIA and ELEVATE-TN studies in chronic lymphocytic leukemia.
Participants Discuss PI3K Inhibitors and Endocrine Resistance in Metastatic Breast Cancer
During a a live event, Virginia Kaklamani, MD, DSc, and participants discussed their experiences using a PI3K/AKT inhibitor in patients with metastatic breast cancer.
Krivak on PARP Inhibitors and Maintenance Therapy in Ovarian Cancer
In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in patients with advanced ovarian cancer.
